Neural transplantation in the central nervous system umbilical cord. The yardstick for evaluating these new cell types as safe and efficacious graft sources undoubt-has been established as an efficacious therapy in animal models of neurological disorders. Over the last two de-edly will be measured by the same high standards used for fetal neural transplantation. cades, we have witnessed the transfer of such therapy from the laboratory to the clinic. In recent years, modest Laboratory investigations of traditional, current, and new transplantation procedures have transformed the to excellent clinical improvements have been noted in transplanted Parkinson's disease patients, which are in field into a major neuroscience area. Indeed, neuroscience-related papers comprised 37% (64 of the total 174) stark contrast to the early clinical trials with autologous adrenal chromaffin cell grafts. Owing in part to carefully of the articles published in Cell Transplantation during 2000 and 2001. Of note, a report of CT articles pub-planned and designed clinical trials (i.e., adding of placebo controls), the impetus for proceeding with clinical lished in 1998 and 1999 revealed 38% were neuroscience related, indicating CT authors' strong contribution neural transplantation therapy can be equally attributed to rigorous laboratory studies that are focused on opti-to neuroscience was maintained over the last 4 years.
In examining the direction CT has taken during this mizing the therapeutic outcomes by refinement of existing and/or developing new transplantation procedures.
period, we provide a listing of neuroscience-related articles published in CT during 2000 and 2001 . As shown Increasing the viability of donor cells prior to and after grafting remains a main obstacle for successful trans-in Table 1 , articles are categorized into a number of important subjects in which they are relevant. In agreement plantation. However, recent laboratory data offer possible solutions. For example, better hibernation media and with the earlier report (47a), CT remains a choice for publishing neural transplantation articles with neurosci-cryopreservation techniques have now been made available, which demonstrate increased viability of donor ence emphasis. As noted above, evaluations of transplantation protocols have surged over recent years as cells, as well as graft survival. Whereas modulating the host immune system continues to occupy center stage as reflected in the increased number of articles published in the format of Reviews [10] and Methods [14] . Com-a major target for enhancing graft survival, long-term positive results with immunoisolation therapy (i.e., en-pared to the previous CT analysis of published articles, there is 100% increase in papers on Huntington's dis-capsulation of cells) suggest its larger role especially in xenotransplantation. In parallel, a high breed of immu-ease [9], and new fields of endeavor have been explored, such as Stroke [4] , Bone marrow [4] , and Amniotic epi-nosuppressants has been introduced as potentially better immunomodualtors, and may even serve as neuroprotec-thelial cells [3] . , Clinical ogy in cell sorting designed to provide homogenous cell populations has also shown feasibility in transplantation [6] , Gene Therapy [4] , Spinal Cord [4] , Alzheimer's disease [3] , Nonhuman Primate Research [3] , Retina [3] , studies. Of course, we cannot ignore the landmark entry of nonfetal primary cells as alternative graft sources, and Pain [2] . The field has matured from one that was broadly specifically stem cells derived from bone marrow and 616 BORLONGAN AND SANBERG "phenomenon discovery" to one that has emphasized A molecular basis of cryopreservation failure and its mod-"mechanism-based" investigations. We believe that real- 
